HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schmidt, N. J. Articles by Lennette, E. H. Search for Related Content PubMed PubMed Citation Articles by Schmidt, N. J. Articles by Lennette, E. H.

Studies on the Hemagglutination of Coe (Coxsackie A21) Virus¹

From the Viral and Rickettsial Disease Laboratory, California State Department of Public Health, Berkeley 4, California

Abstract

Hemagglutinin could be demonstrated in HeLa cell cultures infected with all 16 of the Coe virus strains examined, including the prototype Coe strain and the prototype Coxsackie A21 strain, but certain preparations required treatment with the fluorocarbon, Genetron 113, to "unmask" the hemagglutinin. Two viral strains carried for 20 or more passages in HeLa cell cultures showed no diminution in ability to produce hemagglutinin in this cell type.

The optimal pH for demonstration of Coe virus hemagglutinins was found to be in the range of 5.8 to 6.8.

The hemagglutinating capacity of Coe virus would appear to be largely associated with the infectious particle as absorption of hemagglutinating viral preparations with human group O cells removed considerable infectivity as well as hemagglutinin. Also, the development of HA activity in infected cell cultures closely paralleled the development of infectious virus.

Inhibitors of Coe virus hemagglutination were demonstrated in HeLa cell cultures infected with dilute viral inocula and also in uninfected cell culture fluids. Inhibitors present in uninfected culture fluids were nondialyzable and stable at 56°C for 30 min.

Footnotes

¹ These studies were conducted under the auspices of the Commission on Influenza, Armed Forces Epidemiological Board, and supported by the Office of The Surgeon General, Department of the Army and by Grants E-1475 and EP-3938 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, U. S. Public Health Service.